Evidence map›Paper›PMID 35693806›Full record

ArticleFrontiers in immunology2022

A SARS-CoV-2 Spike Receptor Binding Motif Peptide Induces Anti-Spike Antibodies in Mice andIs Recognized by COVID-19 Patients.

Federico Pratesi, Fosca Errante, Lorenzo Pacini, Irina Charlot Peña-Moreno, Sebastian Quiceno, Alfonso Carotenuto, Saidou Balam, Drissa Konaté, Mahamadou M Diakité, Myriam Arévalo-Herrera and 6 more

Expression of concernOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 6 countries.

Federico PratesiDepartment of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Fosca ErranteInterdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy.
Lorenzo PaciniInterdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy.
Irina Charlot Peña-MorenoDepartment of Immunology, Caucaseco Scientific Research Center, Cali, Colombia.
Sebastian QuicenoDepartment of Immunology, Caucaseco Scientific Research Center, Cali, Colombia.
Alfonso CarotenutoDepartment of Pharmacy, University of Naples Federico II, Naples, Italy.
Saidou BalamImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Drissa KonatéImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Mahamadou M DiakitéImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Myriam Arévalo-HerreraDepartment of Immunology, Malaria Vaccine and Drug Development Center, Cali, Colombia.
Andrey V KajavaCRBM, University of Montpellier, CNRS, Montpellier, France.
Paolo RoveroInterdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy.
Giampietro CorradinBiochemistry Department, University of Lausanne, Lausanne, Switzerland.
Paola MiglioriniDepartment of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Anna M PapiniInterdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy.
Sócrates HerreraDepartment of Immunology, Caucaseco Scientific Research Center, Cali, Colombia.
Caucaseco Scientific Research Center · COUniversity of Florence · ITAzienda Ospedaliera Universitaria Pisana · ITUniversité des Sciences, des Techniques et des Technologies de Bamako · MLUniversité de Montpellier · FRUniversity Hospital Regensburg · DEUniversity of Lausanne · CHUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The currently devastating pandemic of severe acute respiratory syndrome known as coronavirus disease 2019 or COVID-19 is caused by the coronavirus SARS-CoV-2. Both the virus and the disease have been extensively studied worldwide. A trimeric spike (S) protein expressed on the virus outer bilayer leaflet has been identified as a ligand that allows the virus to penetrate human host cells and cause infection. Its receptor-binding domain (RBD) interacts with the angiotensin-converting enzyme 2 (ACE2), the host-cell viral receptor, and is, therefore, the subject of intense research for the development of virus control means, particularly vaccines. In this work, we search for smaller fragments of the S protein able to elicit virus-neutralizing antibodies, suitable for production by peptide synthesis technology. Based on the analysis of available data, we selected a 72 aa long receptor binding motif (RBM

Indexed as

COVID-19SARS-CoV-2AnimalsAntibodies, ViralHumansMicePeptidesSpike Glycoprotein, CoronavirusAntibodies, ViralPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19immunized animalsneutralizing Absreceptor binding motifSARS-CoV-2spike (S) protein

Identifiers

PMID35693806
PMCPMC9178084
OpenAlexW4281551697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.